Original ResearchClinical—Alimentary TractNonsteroidal Anti-inflammatory Drug Use Reduces Risk of Adenocarcinomas of the Esophagus and Esophagogastric Junction in a Pooled Analysis
Section snippets
Study Populations
Among the 12 BEACON studies, we identified 6 with sufficient information on aspirin and nonaspirin NSAID use to contribute to the pooled analyses of EAC (Table 1). Five studies were population-based case-control studies (the Australian Study of Esophageal Cancer,33 the Nova Scotia Barrett Esophagus Study,34 the US Multicenter Study,24 the Factors Influencing the Barrett's Adenocarcinoma Relationship Study,20 and the Los Angeles County Multi-ethnic Study35) and one was a cohort study (the
Results
The included studies are described in Table 1. The mean age of EAC cases, EGJA cases, and controls was 63.7, 63.1, and 61.7 years, respectively. A large majority of cases (EAC, 88.4%; EGJA, 85.8%) and controls (68.1%) were male. The overall prevalence of ever NSAID use among controls was 69%, which varied between studies from 37% to 87%. Overall, the proportion of persons reporting ever using NSAIDs was 56.6% among EAC cases and 59.6% among EGJA cases compared with 68.6% among controls.
Discussion
We found that users of NSAIDs, in particular those reporting current use, experienced a statistically significant lower risk of EAC than those who did not use these medications. We also observed statistically significant inverse associations between greater frequency and duration of NSAID use and risk of EAC. When the analysis was examined by type of NSAID, the magnitude of the effect for ever use of aspirin was similar to the effect for ever use of nonaspirin NSAIDs. However, there was little
References (45)
- et al.
Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence
Am J Gastroenterol
(2001) - et al.
Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study
Lancet Oncol
(2005) - et al.
Use of anti-inflammatory drugs and lower esophageal sphincter-relaxing drugs and risk of esophageal and gastric cancers
Clin Gastroenterol Hepatol
(2007) - et al.
Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis
Gastroenterology
(2003) - et al.
Medication usage and the risk of neoplasia in patients with Barrett's esophagus
Clin Gastroenterol Hepatol
(2009) - et al.
Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus
Gastroenterology
(2010) - et al.
Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials
Lancet
(2011) - et al.
NSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of action
Am J Gastroenterol
(2002) - et al.
Trends in incidence of oesophageal and stomach cancer subtypes in Europe
Eur J Gastroenterol Hepatol
(2010) - et al.
Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005
Br J Cancer
(2009)
Cancer statistics, 2009
CA Cancer J Clin
Changing patterns in the incidence of esophageal and gastric carcinoma in the United States
Cancer
Influence of site classification on cancer incidence rates: an analysis of gastric cardia carcinomas
J Natl Cancer Inst
Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
Nat New Biol
Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa
Nature
Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas
Cancer Res
The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study
J Natl Cancer Inst
Cyclooxygenase-2 inhibitor therapy for the prevention of esophageal adenocarcinoma in Barrett's esophagus
J Natl Cancer Inst
Selective cyclooxygenase-2 inhibition suppresses basic fibroblast growth factor expression in human esophageal adenocarcinoma
Mol Carcinog
Increased expression of cyclooxygenase-2 protein in human gastric carcinoma
Clin Cancer Res
The anti-cancer effect of COX-2 inhibitors on gastric cancer cells
Dig Dis Sci
Cyclooxygenase-2 inhibition and gastric cancer
Curr Pharm Des
Cited by (134)
Low-dose acetylsalicylic acid for cancer prevention considering risk factors: a retrospective cohort study
2023, Annals of EpidemiologyCurrent Status of Chemoprevention in Barrett's Esophagus
2021, Gastrointestinal Endoscopy Clinics of North AmericaEpidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma: Implications for Screening and Surveillance
2021, Gastrointestinal Endoscopy Clinics of North AmericaEsophagus and Gastrointestinal Junction Tumors
2020, Surgical Clinics of North America
This article has an accompanying continuing medical education activity on page e22. Learning Objective: Upon completion of this assessment, successful learners will be able to understand the epidemiological evidence supporting the association between NSAID use and esophageal adenocarcinoma.
Conflicts of interest The authors disclose no conflicts.
Funding Supported in part by the Intramural Program of the National Institutes of Health (NIH). The US Multicenter Study was funded by U01-CA57949 (to T.L.V.), U01-CA57983 (to M.D.G.), and U01-CA57923 (to H.A.R). The Los Angeles County Multi-ethnic Study was funded by 3RT-0122 (“Smoking and Risk of Proximal Vs. Distal Gastric Cancer,” to A.H.W.) and 10RT-0251 (“Smoking, microsatellite instability & gastric cancers,” to A.H.W.) from the California Tobacco-Related Research Program and CA59636 (to L.B.) from the National Cancer Institute. The Nova Scotia Barrett Esophagus Study was supported by the Nova Scotia Health Research Foundation (“Molecular mechanisms and lifestyle risk factor interactions in the pathogenesis of human esophageal adenocarcinoma,” N419, to A.G.C.). The Factors Influencing the Barrett’s Adenocarcinoma Relationship Study was funded by an Ireland-Northern Ireland Co-operation Research Project Grant sponsored by the Northern Ireland Research and Development Office, and the Health Research Board, Ireland (All-Ireland case-control study of Oesophageal Adenocarcinoma and Barrett’s Oesophagus, to L.J.M. and Harry Comber). The Australian Study of Esophageal Cancer was supported by the Queensland Cancer Fund and the National Health and Medical Research Council of Australia (program no. 199600, to D.C.W., Adele C. Green, Nicholas K. Hayward, Peter G. Parsons, David M. Purdie, and Penelope M. Webb). The NIH-AARP Diet and Health Study was funded by the Intramural Program of the NIH.